C4 Therapeutics, Inc.

Day range

$2.97 – $3.07

Open

$3.07

Prev close

$3.06

Volume

2.03M

Market cap

$376.46M

Shares out

123.03M

P/E

—

P/S

10.74

P/B

1.52

P/FCF

—

ROE

-41.0%

ROA

-28.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 25, 2026

  In 62 heavily pre-treated RRMM patients across the once-daily (QD) dose levels, cemsidomide demonstrated coordinated activation of T cells, including CD8+ T cells, and functional reprogramming of natural killer (NK) cells. Notably, enhanced immune cell function was observed at the highest dose levels studied (75 µg and 100 µg), which also achieved compelling overall response rates in the Phase 1 trial.

• Investor presentationJun 11, 2026

  On June 11, 2026, C4 Therapeutics, Inc. (the "Company") posted a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

• Executive officer departureMay 15, 2026

  On May 12, 2026, C4 Therapeutics, Inc. (the "Company") determined that Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026. Mr. Mossler's departure from the Company is not due to any disagreement with the Company or the Company's Board of Directors on any matter relating to the Company's financial reporting, operations, policies or practices.

• Investor presentationMay 12, 2026

  On May 12, 2026, the Company posted a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations. A copy of the presentation is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

• Bylaw amendmentApr 10, 2026

  On April 9, 2026, the Board of Directors (the "Board") of C4 Therapeutics, Inc. (the "Company") approved an amendment to the Company's second amended and restated by-laws (the "By-laws Amendment"), effective immediately, to designate the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder.

Days to cover

17.6

Short interest

40.4M

Avg volume

2.29M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
  positiveZacks Investment Research· Oct 9, 2026
• C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
  positiveGlobeNewswire Inc.· Sep 25, 2026
• C4 Therapeutics to Participate in Upcoming Conferences
  neutralGlobeNewswire Inc.· May 20, 2026
• C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
  positiveGlobeNewswire Inc.· Feb 4, 2026
• C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
  positiveGlobeNewswire Inc.· Jan 14, 2026